Home » Idera, Merck KGaA to Develop TLR9 Agonists
Idera, Merck KGaA to Develop TLR9 Agonists
Idera Pharmaceuticals has signed an agreement with Germany’s Merck KGaA for the development and commercialization of Idera’s Toll-like Receptor 9 (TLR9) agonists to treat cancer.
Idera has agreed to license the therapeutic oncology applications, excluding cancer vaccines, of its lead TLR9 agonists, IMO-2055 and IMO-2125. In addition, Idera and Merck KGaA will identify a specified number of novel, follow-on TLR9 agonists.
Merck KGaA has agreed to pay an upfront license fee of $40 million to Idera, which also is eligible to receive milestone payments of up to $381 million, according to Idera.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May